403 related articles for article (PubMed ID: 24145348)
1. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
Park J; Huang D; Chang YJ; Lim MC; Myung SK
Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Cibula D; Zikan M; Dusek L; Majek O
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
[TBL] [Abstract][Full Text] [Related]
5. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
6. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
7. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
[TBL] [Abstract][Full Text] [Related]
10. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
Arch Gynecol Obstet; 2020 Apr; 301(4):875-884. PubMed ID: 32140806
[TBL] [Abstract][Full Text] [Related]
11. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Friebel TM; Domchek SM; Rebbeck TR
J Natl Cancer Inst; 2014 Jun; 106(6):dju091. PubMed ID: 24824314
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
Iodice S; Barile M; Rotmensz N; Feroce I; Bonanni B; Radice P; Bernard L; Maisonneuve P; Gandini S
Eur J Cancer; 2010 Aug; 46(12):2275-84. PubMed ID: 20537530
[TBL] [Abstract][Full Text] [Related]
14. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Eoh KJ; Park EY; Chang YJ; Ha HI; Hong J; Huang D; Nam EJ; Lim MC
Gynecol Oncol; 2021 Oct; 163(1):142-147. PubMed ID: 34304906
[TBL] [Abstract][Full Text] [Related]
15. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
16. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
17. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
[TBL] [Abstract][Full Text] [Related]
19. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
20. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
